Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
Top Page
Scholar Rock Holding
(NASDAQ:SRRK)
Select Model
Select Model
Rating:54Neutral
Price Target:
$42.00
▼(-5.00% Downside)
Action:ReiteratedDate:03/05/26
The score is held back primarily by weak financial performance (zero revenue, expanding losses, and substantial cash burn), which increases financing risk. Offsetting this, the latest earnings call highlighted meaningful regulatory and commercial progress toward a 2026 launch and improved funding flexibility, while technicals are constructive with the stock trading above major moving averages. Valuation remains challenging given negative earnings.
Positive Factors
Regulatory engagement and BLA resubmission readiness
Active, specific FDA engagement and a confirmed plan to resubmit the BLA after a Catalent reinspection materially improves the company's pathway to approval. This reduces execution uncertainty vs. passive dialogue, enabling a clearer timeline to commercialization and revenue realization if inspection outcomes are favorable.
Negative Factors
Zero revenue and high, worsening cash burn
The company is a development‑stage biotech with no product revenue and steep, growing operating losses that translate into large negative cash flows. Persistent high burn elevates refinancing and dilution risk, making long‑term viability contingent on timely approvals, milestone payments, or significant external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory engagement and BLA resubmission readiness
Active, specific FDA engagement and a confirmed plan to resubmit the BLA after a Catalent reinspection materially improves the company's pathway to approval. This reduces execution uncertainty vs. passive dialogue, enabling a clearer timeline to commercialization and revenue realization if inspection outcomes are favorable.
Read all positive factors
Scholar Rock Holding (SRRK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.08B
Dividend YieldN/A
Average Volume (3M)1.34M
Price to Earnings (P/E)―
Beta (1Y)1.67
Revenue GrowthN/A
EPS Growth-31.71%
CountryUS
Employees128
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.88
Shares Outstanding114,883,095
10 Day Avg. Volume1,620,847
30 Day Avg. Volume1,343,404
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.93K
Enterprise Value/Ebitda-13.17
Forecast
1Y Price Target
$57.33Price Target Upside29.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.14
Revenue Forecast (FY)$19.72M
Scholar Rock Holding Business Overview & Revenue Model
Company Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops ...
How the Company Makes Money
Scholar Rock has historically generated revenue primarily through collaboration and license arrangements rather than product sales. Under these agreements, it may earn (i) upfront payments when a collaboration or license is signed, (ii) research a...
Scholar Rock Holding Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call conveyed strong forward momentum: focused regulatory engagement with FDA (including a field visit), readiness to resubmit the BLA following an expected reinspection, an advancing clinical pipeline (multiple studies including FSHD and SRK‑439), active commercial build (field team, specialty pharmacy and home infusion networks), and materially strengthened financing optionality (warrant proceeds plus a $550M debt facility). The key negative is continued regulatory and manufacturing risk tied to Catalent’s remediation status, plus high pre‑launch operating spend and potential payer access timing issues. On balance, the highlights—substantive regulatory engagement, concrete mitigation steps (second fill‑finish facility), robust pipeline progress, commercial preparedness, and improved liquidity—outweigh the remaining execution risks.Positive Updates
Regulatory momentum toward U.S. resubmission and 2026 launch
Company reaffirmed guidance to resubmit the BLA and target a U.S. launch upon approval in 2026. Since the November Type A meeting, FDA engagement has been active (including an FDA field team visit to the Catalent, IN site) and the FDA indicated intent to reinspect the Catalent facility after routine manufacturing resumed in late February. Management is prepared to resubmit the BLA quickly following a successful reinspection.
Negative Updates
Manufacturing compliance at Catalent created sole approvability issue
FDA warning letter to Catalent (Indiana) was cited as the sole approvability issue in the prior CRL. The BLA resubmission gating item remains a successful FDA reinspection of Catalent; timing and outcome of that reinspection introduce material uncertainty and potential delays to resubmission/approval.
Read all updates
Q4-2025 Updates
Positive
Negative
Regulatory momentum toward U.S. resubmission and 2026 launch
Company reaffirmed guidance to resubmit the BLA and target a U.S. launch upon approval in 2026. Since the November Type A meeting, FDA engagement has been active (including an FDA field team visit to the Catalent, IN site) and the FDA indicated intent to reinspect the Catalent facility after routine manufacturing resumed in late February. Management is prepared to resubmit the BLA quickly following a successful reinspection.
Read all positive updates
Company Guidance
Scholar Rock reaffirmed guidance to resubmit the BLA and achieve a U.S. launch following approval in 2026 (contingent on a successful FDA reinspection of the Catalent, Indiana site) and expects an EMA decision in mid‑2026, with a supplemental BLA for a second fill‑finish facility planned later in 2026; pipeline milestones include ongoing enrollment in the Phase 2 OVAL study, a 60‑patient Phase 2 FORGE study in FSHD planned to start mid‑2026, and top‑line Phase 1 data for SRK‑439 expected in H2 2026. Financially, the company ended 2025 with $368.0M in cash (including $60.4M from warrant exercises), reported Q4 operating expenses of $91.9M (SBC $19.4M; ex‑SBC $72.5M) and full‑year 2025 OpEx of $384.6M (SBC $75.6M; ex‑SBC $309.0M), and secured a debt facility of up to $550M ( $100M available and used immediately to repay prior debt, an additional $100M expected to be drawn by March 31, a $150M option upon FDA approval, and an optional incremental $200M by mutual consent) and intends to monetize a priority review voucher as additional balance‑sheet support. Commercial readiness metrics highlighted: engagement across ~140 SMA treatment centers, ~2,600 prescribing physicians, an expanded specialty‑pharmacy network, and a home‑infusion network of >10,000 affiliated nurses, targeting a market where SMN‑targeted therapies represent nearly $5.0B in annual global sales and where ~95% of patients continue to experience progressive muscle weakness.Scholar Rock Holding Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 33.19M | 18.82M |
| Gross Profit | -1.66M | -1.94M | -2.84M | -89.85M | -89.65M |
| EBITDA | -369.39M | -237.52M | -162.94M | -129.48M | -127.29M |
| Net Income | -377.94M | -246.29M | -165.79M | -134.50M | -131.80M |
Balance Sheet | |||||
| Total Assets | 404.27M | 474.92M | 311.04M | 358.17M | 304.44M |
| Cash, Cash Equivalents and Short-Term Investments | 367.56M | 437.28M | 279.94M | 315.36M | 252.99M |
| Total Debt | 108.92M | 65.13M | 61.82M | 69.40M | 84.47M |
| Total Liabilities | 158.78M | 106.29M | 85.82M | 97.93M | 132.37M |
| Stockholders Equity | 245.49M | 368.63M | 225.22M | 260.24M | 172.07M |
Cash Flow | |||||
| Free Cash Flow | -300.64M | -201.05M | -145.30M | -133.76M | -132.04M |
| Operating Cash Flow | -300.04M | -200.95M | -145.23M | -132.69M | -126.79M |
| Investing Cash Flow | 218.69M | -76.06M | 41.14M | -171.70M | 134.31M |
| Financing Cash Flow | 228.40M | 353.03M | 102.57M | 194.83M | 44.95M |
Scholar Rock Holding Technical Analysis
Positive
44.21
Price Trends
45.13
Negative
42.75
Positive
38.57
Positive
Market Momentum
-0.43
Negative
50.48
Neutral
57.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRRK, the sentiment is Positive. The current price of 44.21 is above the 20-day moving average (MA) of 43.57, below the 50-day MA of 45.13, and above the 200-day MA of 38.57, indicating a neutral trend. The MACD of -0.43 indicates Negative momentum. The RSI at 50.48 is Neutral, neither overbought nor oversold. The STOCH value of 57.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRRK.
Scholar Rock Holding Risk Analysis
Scholar Rock Holding disclosed 70 risk factors in its most recent earnings report. Scholar Rock Holding reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scholar Rock Holding Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $5.20B | -10.27 | -55.81% | ― | ― | -38.30% | |
62 Neutral | $5.16B | -10.43 | -65.80% | ― | ― | -27.70% | |
55 Neutral | $3.59B | -19.69 | -28.29% | ― | ― | ― | |
54 Neutral | $5.08B | -13.37 | -145.91% | ― | ― | -31.71% | |
52 Neutral | $3.96B | -6.36 | -48.04% | ― | ― | -126.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.93B | -3.94 | -1024.42% | ― | 20.63% | 8.09% |
* Healthcare Sector Average
SRRK
Scholar Rock Holding
44.21
10.85
32.52%
RARE
Ultragenyx Pharmaceutical
20.00
-18.89
-48.57%
VKTX
Viking Therapeutics
34.25
8.12
31.08%
XENE
Xenon
55.53
21.07
61.14%
IMVT
Immunovant
25.36
6.57
34.97%
NAMS
NewAmsterdam Pharma Company
31.25
8.84
39.45%
Scholar Rock Holding Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Scholar Rock Advances Apitegromab Toward SMA Commercial Launch
Positive
Mar 3, 2026
On March 3, 2026, Scholar Rock reported fourth-quarter and full-year 2025 results, highlighting rapid progress toward bringing its lead SMA therapy apitegromab to market despite continued losses. The company is positioning itself as a key player i...
Business Operations and StrategyFinancial Disclosures
Scholar Rock Details 2026 Strategy and Regulatory Priorities
Positive
Jan 12, 2026
On January 12, 2026, Scholar Rock issued a corporate update outlining 2026 strategic priorities centered on securing U.S. and European regulatory approvals and commercial launch for apitegromab in children and adults with SMA, expanding developmen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.